^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MAP2K1 F129L

i
Entrez ID:
Related biomarkers:
over3years
NGS-based liquid-biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step towards personalized NSCLC treatment. (PubMed, Mol Oncol)
Finally, a c-MYC gain, along with a loss of CCND1 and FGFR3, were detected in a patient progressing on a first-line treatment with crizotinib. We conclude that NGS analysis of liquid biopsies upon disease progression identified different putative ALK-I-resistance mutations in most cases, and could be a valuable approach for therapy decision making.
Journal • Liquid biopsy • Next-generation sequencing
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • CCND1 (Cyclin D1) • SMAD4 (SMAD family member 4) • CCND3 (Cyclin D3)
|
TP53 mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • EGFR exon 19 deletion • ALK positive • FGFR2 mutation • ALK mutation • MAP2K1 mutation • ALK G1202R • ALK G1269A • BRAF G466V • MAP2K1 F129L
|
Xalkori (crizotinib)